However, the characteristic immunophenotype of BL and MYC translocations can also be detected in a subset of diffuse large B-cell lymphoma (DLBCL) 2 making the distinction between these two entities sometimes problematic. This is of importance clinically, since the therapeutic approaches for BL and DLBCL differ substantially. 3 A further complication is introduced by the diagnostic category of atypical BL, which is used for aggressive B-cell lymphomas carrying the immunophenotype of classic BL and a MYC translocation, but in which the morphological and/or immunophenotypic features are slightly atypical. 1 Two major gene expression profiling studies recently sharpened the molecular distinction between BL and DLBCL. 4, 5 Whereas virtually all lymphomas diagnosed as classic or atypical BL according to the current World Health Organization (WHO) criteria 1 showed gene expression profiles characteristic of BL, a subset of DLBCL had the typical gene expression signature of BL suggesting that these cases correspond to BL at the molecular level. 4 Moreover, some of the cases with a clear-cut gene expression profile of BL showed expression of bcl2 and a Ki-67 index below 90% by immunohistochemistry thus extending the molecular category of BL beyond currently accepted criteria. 4 In recent years, global genetic analyses including conventional karyotyping, comparative genomic hybridization (CGH) and array-based CGH have described secondary genomic alterations in BL. [6] [7] [8] [9] [10] [11] [12] [13] One of the larger studies using CGH described gains of 12q, 22q, Xq and losses of 13q as the most frequent alterations in BL. 11 Moreover, abnormalities in 1q and 7q were associated with inferior outcome. 11 A recent combined cytogenetic study including CGH and spectral karyotyping (SKY) identified frequent gains of chromosome 7
and losses of 17p in a panel of ten BL cell lines. 12 Using classical cytogenetic analysis in 39
Burkitt-like lymphomas, however, gains of chromosome 12 and losses of chromosomes 13
and 15 appeared to be the most frequent secondary genetic alterations in addition to the MYC translocation. 13 This study was designed to investigate secondary genomic alterations in gene expressiondefined BL 4 using conventional CGH. In particular, we addressed the questions of whether:
(i) morphological subgroups of molecularly defined BL (classic BL, atypical BL and discrepant BL) differ in underlying genetic alterations, (ii) pediatric and adult BL show differences in their genetic and gene expression profiles, and (iii) genetic alterations in BL lead to consequences in locus-specific or global gene expression profiles.
PaTiEnTs anD METHoDs

Characteristics of the patients
We studied 51 patients with a gene expression signature of BL. 4 Information on these pa- The correlation between chromosomal alterations and the previously described gene expression signatures in BL 4 was established as follows. The signatures "MYC and target genes", "NFkB target genes", "MHC class I genes" and the germinal center B-cell gene signatures "BL-high", "BL-low" and "BL=GCB" were each averaged. For each band which included four or more losses, a t-test was computed between those BL samples with losses, and those BL samples with a wild type copy number. These results were then adjusted for multiple comparisons using the stepwise permutation test. An identical analysis was performed for BL cases showing gains/amplifications versus those harboring a wild type copy number.
rEsuLTs
Chromosomal imbalances in Burkitt lymphoma
The clinical characteristics of the patients with gene expression-defined BL are summarized in Table 1 . The median age of the patients was 29 years (range, 3-91 years). Interestingly, patients with morphologically discrepant BL were significantly older (median age 61;
range, 27-91) than patients with classic BL (median age 18; range, 3-67) or atypical BL (median age 31; range, 3-73) (p<0.01). The male/female ratio was 37:6 in patients with classic and atypical BL, but 4:4 in discrepant BL. Twenty-seven patients received multi-agent chemotherapy, including 20 patients who received intensive chemotherapy regimens, and no information on the treatment was available for 24 patients. Among the 51 BL cases studied, 36 (71%) showed genetic alterations by CGH. The total number of alterations was 122 (68 gains, 13 amplifications and 41 losses) ( Figure 1A ). Overall, the most frequent gains were 1q, 7/7q, 8q24-qter, 13q31-q32, and the most frequent loss occurred in 17p. Among the 26 cases of classic BL, 17 (65%) showed aberrant profiles by CGH analysis, whereas no chromosomal imbalances were detected in 9 cases. Among aberrant cases, 25 gains, 4
amplifications and 10 losses of chromosomal material were observed, the most frequent chromosomal alterations being gains of different regions of 1q and chromosome 7 ( Figure   1B , Table 2 ). Twelve of 17 atypical BL (59%) showed aberrant CGH profiles demonstrating 13 gains, 3 amplifications and 10 losses. Most frequently, we observed losses of 17p12-pter and amplifications of 13q31-q32 ( Figure 1C ). Finally, all of the discrepant BL showed CGH alterations with a total of 30 gains, 6 amplifications and 21 losses. This subset showed complex karyotypes with a median of 6.9 alterations per case ( Figure 1D ) and the presence of the t(14;18) translocation was detected in three out of five cases investigated (besides an underlying translocation involving MYC that was present in all cases). Correlations between CGH alterations and clinical parameters (overall survival) were not performed due to the small size of the respective subgroups and the fact that not all patients received intensified treatment regimens.
Comparison of genomic imbalances between Burkitt lymphoma subgroups
No differences in genomic imbalances were observed between classic and atypical BL.
Although chromosomal gains in 1q appeared to be more common in classic BL, this was not statistically significant when accounting for multiple testing. 
Comparison of genomic imbalances between Burkitt lymphoma and DLBCL
A comparison of genomic imbalances between BL and 161 previously studied DLBCL 14 showed that losses of 11q24-q25 were present in BL but uncommon in DLBCL (p=0.03)
whereas there was a trend towards more gains/amplifications of 18q21-q23 in DLBCL compared to in BL (p=0.1) Comparing BL with the molecular subgroups of DLBCL, the frequently observed gains of chromosome 3 in ABC DLBCL were infrequent in BL (p=0.035),
as were gains in 18q21-q23 (p=0.01) and losses of 6q16-q27 (p=0.02). No statistically significant differences were found regarding the genetic constitution of BL and the GCB DLBCL subgroup. groups (27 adult and 24 pediatric cases). Nineteen of the 27 adult patients (70%) and 18
of the 24 pediatric cases (75%) displayed detectable alterations. Overall, adult BL patients had a significantly higher complexity of abnormalities than pediatric cases (3.1 abnormalities per tumor in adults versus 1.5 in the pediatric group). Further analysis showed that this was entirely accounted for by the group of eight discrepant BL. Excluding these cases from the adult group, the complexity (both 1.5 abnormalities per tumor) and also the pattern of alterations was similar in adult and pediatric BL (Figure 2A and 2B). Based on these results, we tested whether differences in overall gene expression exist between pediatric and adult BL. Searching the gene expression data generated previously on an Affymetrix custom oligonucleotide micro-array with 2524 unique genes, 4 no statistically significant differences could be detected and the attempt to establish a gene expression-based predictor of pediatric and adult BL failed (data not shown).
impact of chromosomal imbalances on locus-specific gene expression in Burkitt lymphoma
The six chromosomal regions that were most frequently altered were studied to determine the impact of specific chromosomal gains or losses on locus-specific gene expression levels. These were the regions 1cen-q22, 1q31-q32, 7q22-qter, 8q24-qter, 13q31-q32, and 17p13-pter. As demonstrated in previous analyses, 14,17 chromosomal imbalances were associated with elevated or reduced expression of a subset of genes within the involved chromosomal regions. In the chromosomal region 1cen-q22, for example, 10 out of 23 genes (43%) represented on the custom micro-array in the respective region, showed increased expression levels in cases with gains as compared to cases with two copies. In particular, in this region the levels of expression of NOTCH, BCL9, CKIP-1, MCL1, PSMB4, ILF2, JTB, HAX1, ATP8B2, and CKS1B were found to be elevated ( Figure 3A ). Significantly fewer genes (20%) were upregulated in the chromosomal region 1q31-q32 ( Figure 3B) . The results for 
impact of chromosomal imbalances on biologically relevant gene expression signatures in Burkitt lymphoma
In a previous study, 4 we had defined gene expression signatures that distinguish BL from DLBCL. In particular, the signatures "NFkB target genes" and "MHC class I genes" were expressed at very low levels in BL, whereas, by the very nature of the pathogenesis of BL, the "MYC and target genes" signature is increased. Germinal center B cell-associated genes showed a heterogeneous picture including genes expressed more highly in BL ("BL-high" signature), genes with reduced expression levels ("BL-low" signature) and genes with equal expression between BL and DLBCL (BL=GCB signature). 4 Here, we sought to determine
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whether certain genetic alterations in BL were associated with increased or decreased expression of any of these signatures, since the altered chromosomal regions may harbor master regulators of these pathways. Indeed, gains of the 17q11-q25 region were associated with increased expression of the NFkB signature (p=0.046), whereas gains of different regions of chromosome 1 (1cen-q12 and 1q21-q32) were associated with the specific "BL-high" signature (p=0.035) and the more general germinal center associated "BL=GCB" signature (p=0.04).
DisCussion
Although a number of previous studies described genetic alterations in BL, [6] [7] [8] [9] [10] [11] [12] [13] of the discrepant BL in our study. These lymphomas have been described in earlier reports and are characterized by an extremely aggressive clinical course that is fatal in almost all cases. 13, 18 It is unlikely that in these dual translocation cases the potentially secondary rear- Another major aim of this study was to compare gene expression and genetic features between pediatric and adult cases of BL. Currently, pediatric BL patients are treated in prospective clinical trials separately from adult BL patients. However, the adaptation of therapeutic protocols initially designed for pediatric patients to adults has led to improved survival times for adult BL patients in recent years. 19, 20 Gene expression data 4 and, in addition, genetic data obtained in the current report failed to provide evidence that molecular differences exist between pediatric and adult BL. Our CGH analysis revealed genetic imbalances in 75% of pediatric and 70% of adult BL patients and the spectrum of genetic alterations did not differ between the two groups. Moreover, no gene expression-based predictor could be constructed that was able to distinguish between patients with molecular BL in dif- In summary, we show that classic and atypical BL carrying a molecular profile of BL, as defined by gene expression profiling, do not differ in gene expression or underlying chromosomal alterations, whereas a subset of discrepant BL, despite its BL-characteristic gene expression profile, may form a genetic entity distinct from classic and atypical BL as well as DLBCL. Furthermore, we failed to identify gene expression or genetic differences between molecularly defined cases of pediatric and adult BL supporting the notion that BL in both age groups should be viewed as one molecular entity.
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